NO20071005L - Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer - Google Patents

Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer

Info

Publication number
NO20071005L
NO20071005L NO20071005A NO20071005A NO20071005L NO 20071005 L NO20071005 L NO 20071005L NO 20071005 A NO20071005 A NO 20071005A NO 20071005 A NO20071005 A NO 20071005A NO 20071005 L NO20071005 L NO 20071005L
Authority
NO
Norway
Prior art keywords
cancer
pyrimidones
enantiomers
prevention
applications
Prior art date
Application number
NO20071005A
Other languages
English (en)
Inventor
Michael Howard Block
Jayachandran Ezhuthachan
Brian Aquila
Audrey Davies
Timothy Pontz
Maria-Elena Theoclitou
Xiaolan Zheng
Daniel John Russell
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37904998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071005(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/GB2005/003207 external-priority patent/WO2006018628A1/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20071005L publication Critical patent/NO20071005L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Foreliggende oppfinnelse angår nye forbindelser som har strukturell formel (I) og deres farmasøytiske preparater og fremgangsmåter for anvendelse derav. Disse nye forbindelsene kan anvendes for behandling eller forebygging av kreft.
NO20071005A 2004-08-18 2007-02-21 Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer NO20071005L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60236604P 2004-08-18 2004-08-18
PCT/GB2005/003207 WO2006018628A1 (en) 2003-03-07 2005-08-16 Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer

Publications (1)

Publication Number Publication Date
NO20071005L true NO20071005L (no) 2007-05-16

Family

ID=37904998

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071005A NO20071005L (no) 2004-08-18 2007-02-21 Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer

Country Status (18)

Country Link
US (3) US20080293744A1 (no)
EP (1) EP1781674A1 (no)
JP (1) JP2008509977A (no)
KR (1) KR20070046176A (no)
CN (1) CN101027309B (no)
AU (1) AU2005273705B8 (no)
BR (1) BRPI0514390A (no)
CA (1) CA2575188A1 (no)
IL (1) IL180810A0 (no)
MX (1) MX2007001953A (no)
MY (1) MY141233A (no)
NO (1) NO20071005L (no)
RU (1) RU2447077C2 (no)
SA (1) SA05260258B1 (no)
TW (1) TW200616977A (no)
UA (1) UA89201C2 (no)
UY (1) UY29070A1 (no)
ZA (1) ZA200701082B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503193A (ja) * 2007-11-13 2011-01-27 アイコス、コーポレーション ヒトホスファチジルイノシトール３−キナーゼδの阻害剤
ES2486715T3 (es) 2009-06-29 2014-08-19 Incyte Corporation Pirimidinonas como inhibidores de PI3K
LT2751109T (lt) 2011-09-02 2017-02-27 Incyte Holdings Corporation Heterociklilaminai kaip pi3k inhibitoriai
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN105793255B (zh) 2013-10-04 2018-11-16 无限药品股份有限公司 杂环化合物及其用途
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2024103067A1 (en) * 2022-11-10 2024-05-16 Ribometrix, Inc. COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792767A (en) 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
ES2176697T3 (es) 1996-03-11 2002-12-01 Syngenta Participations Ag Derivados pirimidin-4-ona como pesticidas.
BR9917080A (pt) 1998-12-23 2002-03-12 Du Pont Pharm Co Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
DE60017157T2 (de) 1999-09-16 2005-12-22 Curis, Inc., Cambridge Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
KR20050049562A (ko) 1999-10-27 2005-05-25 싸이토키네틱스, 인코포레이티드 퀴나졸리논을 사용하는 방법 및 조성물
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
KR100883184B1 (ko) 2000-12-11 2009-02-12 암젠 인코포레이션 Ｃｘｃｒ3 길항제
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6809102B2 (en) * 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
JP2005506298A (ja) 2001-03-29 2005-03-03 ブリストル−マイヤーズ　スクイブ　カンパニー Ｅｇ５阻害剤を用いる増殖性疾患の治療方法
AU2002305205A1 (en) 2001-04-20 2002-11-05 Jingrong Cao 9-deazaguanine derivatives as inhibitors of gsk-3
WO2003039460A2 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2002346471A1 (en) * 2001-11-20 2003-06-10 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
US7244723B2 (en) * 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
US7262187B2 (en) * 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor
DE60232994D1 (de) * 2001-12-06 2009-08-27 Merck & Co Inc Inhibitoren von mitotischem kinesin
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
JP4597519B2 (ja) 2001-12-06 2010-12-15 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害薬
CA2475879A1 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
US6924376B2 (en) 2002-04-17 2005-08-02 Cytokinetics, Inc. Compounds, compositions and methods
WO2003094839A2 (en) * 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
EP1553931A4 (en) 2002-05-09 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
EP1513820A4 (en) * 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
CA2485343A1 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003099211A2 (en) 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
US7041676B2 (en) 2002-06-14 2006-05-09 Cytokinetics, Inc. Compounds, compositions, and methods
DE60326248D1 (de) * 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
JP2005536553A (ja) 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
AU2003267169A1 (en) 2002-09-13 2004-04-30 Cytokinetics, Inc. Compounds, compositions and methods
US7557115B2 (en) 2002-09-30 2009-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
EP1558589A4 (en) 2002-10-11 2008-01-09 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
MXPA05003830A (es) 2002-10-11 2005-06-23 Cytokinetics Inc Compuestos, composiciones y metodos.
JP2006515886A (ja) 2003-01-17 2006-06-08 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
BRPI0408150A (pt) * 2003-03-07 2006-03-21 Astrazeneca Ab composto, seu uso e processo para preparação do mesmo, métodos para tratamento ou profilaxia de cáncer e para produção de um efeito inibidor do ciclo celular (anti - proliferação celular) em um animal de sangue quente e composição farmacêutica
WO2006018628A1 (en) * 2003-03-07 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
JP2006523232A (ja) 2003-04-10 2006-10-12 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
WO2004100873A2 (en) 2003-05-07 2004-11-25 Cytokinetics, Inc. Compounds, compositions, and methods
EP1622613A4 (en) 2003-05-14 2008-04-02 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
JP2007500746A (ja) 2003-05-15 2007-01-18 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
CN1809563A (zh) 2003-06-20 2006-07-26 希龙公司 吡啶并[1,2－a]嘧啶－4－酮化合物用作抗癌药
US20050165089A1 (en) * 2003-10-06 2005-07-28 Gustave Bergnes Compounds, compositions and methods
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
DK1689724T3 (da) 2003-11-25 2012-02-27 Novartis Ag Quinazolinonforbindelser som anticancermidler
WO2005061460A1 (en) 2003-12-08 2005-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
ATE419249T1 (de) 2004-04-06 2009-01-15 Novartis Vaccines & Diagnostic Inhibitoren von mitotischem kinesin
BRPI0511433A (pt) 2004-05-21 2007-12-11 Chiron Corp derivados de quinolina substituìda como inibidores de cinesina mitótica
MXPA06014909A (es) 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
US20070249636A1 (en) 2004-08-18 2007-10-25 Astrazeneca Ab Selected Fused Heterocyclics and Uses Thereof
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
RU2007118523A (ru) * 2004-10-19 2008-11-27 Новартис Вэксинс Энд Диагностикс Инк. (Us) Производные индола и бензимидазола

Also Published As

Publication number Publication date
SA05260258B1 (ar) 2009-12-22
AU2005273705A1 (en) 2006-02-23
EP1781674A1 (en) 2007-05-09
RU2447077C2 (ru) 2012-04-10
MY141233A (en) 2010-03-31
US20090099210A1 (en) 2009-04-16
UA89201C2 (ru) 2010-01-11
US7498333B2 (en) 2009-03-03
AU2005273705B8 (en) 2010-01-28
US20060041129A1 (en) 2006-02-23
IL180810A0 (en) 2007-06-03
BRPI0514390A (pt) 2008-06-10
TW200616977A (en) 2006-06-01
CN101027309A (zh) 2007-08-29
AU2005273705B2 (en) 2009-12-10
UY29070A1 (es) 2006-03-31
US20080293744A1 (en) 2008-11-27
MX2007001953A (es) 2007-05-09
KR20070046176A (ko) 2007-05-02
ZA200701082B (en) 2008-07-30
JP2008509977A (ja) 2008-04-03
CA2575188A1 (en) 2006-02-23
RU2007109866A (ru) 2008-09-27
CN101027309B (zh) 2010-10-27

Similar Documents

Publication Publication Date Title
NO20071005L (no) Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
EA202092001A1 (ru) Соединения для лечения болезни гентингтона
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20054083L (no) Nye sammenkoblede triazoloner og deres anvendelse
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
WO2018134685A3 (en) Compounds
NO20081454L (no) Met-kinaseinhibitorer
EA201370122A1 (ru) Фармацевтические составы, содержащие ингибиторы деацетилазы гистонов
DK2358717T3 (da) Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
NO20081636L (no) FAP - inhibitorer
NO20054340L (no) Nye sammenkoplede heterocykler og deres anvendelse
DE60331219D1 (de) Azaindole als hemmstoffe von c-jun n-terminalen kinasen
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
NO20083598L (no) Karbosykliske og heterosykliske arylsulfoner som inhibitorer av gamma-sekretase
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
NO20060230L (no) Nye aminobenzofenonforbindelser
NO20080150L (no) Inhibitorer av AKT-aktivitet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application